[HTML][HTML] Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome
JA Coppell, PG Richardson, R Soiffer, PL Martin… - Biology of blood and …, 2010 - Elsevier
Occurrence of hepatic veno-occlusive disease (VOD) has been reported in up to 60% of
patients following stem cell transplantation (SCT). However, the incidence varies widely …
patients following stem cell transplantation (SCT). However, the incidence varies widely …
Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population
PG Richardson, AD Elias, A Krishnan… - Blood, The Journal …, 1998 - ashpublications.org
Hepatic veno-occlusive disease (VOD) is the most common of the regimen-related toxicities
accompanying stem cell transplantation (SCT). Despite aggressive therapies, including the …
accompanying stem cell transplantation (SCT). Despite aggressive therapies, including the …
[HTML][HTML] American society of blood and marrow transplantation, european society of blood and marrow transplantation, blood and marrow transplant clinical trials …
In contrast to the upfront setting in which the role of high-dose therapy with autologous
hematopoietic cell transplantation (HCT) as consolidation of a first remission in patients with …
hematopoietic cell transplantation (HCT) as consolidation of a first remission in patients with …
[HTML][HTML] Teclistamab in relapsed or refractory multiple myeloma
P Moreau, AL Garfall, NWCJ van de Donk… - … England Journal of …, 2022 - Mass Medical Soc
Background Teclistamab is a T-cell–redirecting bispecific antibody that targets both CD3
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …
expressed on the surface of T cells and B-cell maturation antigen expressed on the surface …
[HTML][HTML] Initial genome sequencing and analysis of multiple myeloma
Multiple myeloma is an incurable malignancy of plasma cells, and its pathogenesis is poorly
understood. Here we report the massively parallel sequencing of 38 tumour genomes and …
understood. Here we report the massively parallel sequencing of 38 tumour genomes and …
[HTML][HTML] Talquetamab, a T-cell–redirecting GPRC5D bispecific antibody for multiple myeloma
A Chari, MC Minnema, JG Berdeja… - … England Journal of …, 2022 - Mass Medical Soc
Background G protein–coupled receptor, family C, group 5, member D (GPRC5D) is an
orphan receptor expressed in malignant plasma cells. Talquetamab, a bispecific antibody …
orphan receptor expressed in malignant plasma cells. Talquetamab, a bispecific antibody …
[PDF][PDF] Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy
JG Lohr, P Stojanov, SL Carter, P Cruz-Gordillo… - Cancer cell, 2014 - cell.com
We performed massively parallel sequencing of paired tumor/normal samples from 203
multiple myeloma (MM) patients and identified significantly mutated genes and copy number …
multiple myeloma (MM) patients and identified significantly mutated genes and copy number …
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Background New treatment options are needed for patients with multiple myeloma that is
refractory to proteasome inhibitors and immunomodulatory drugs. We assessed …
refractory to proteasome inhibitors and immunomodulatory drugs. We assessed …
[PDF][PDF] Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma
RI Fisher, SH Bernstein, BS Kahl… - Journal of clinical …, 2006 - academia.edu
Multicenter Phase II Study of Bortezomib in Patients With Relapsed or Refractory Mantle Cell
Lymphoma Page 1 Multicenter Phase II Study of Bortezomib in Patients With Relapsed or …
Lymphoma Page 1 Multicenter Phase II Study of Bortezomib in Patients With Relapsed or …
RNA-Based Gene Therapy for HIV with Lentiviral Vector–Modified CD34+ Cells in Patients Undergoing Transplantation for AIDS-Related Lymphoma
DL DiGiusto, A Krishnan, L Li, H Li, S Li… - Science translational …, 2010 - science.org
AIDS patients who develop lymphoma are often treated with transplanted hematopoietic
progenitor cells. As a first step in developing a hematopoietic cell–based gene therapy …
progenitor cells. As a first step in developing a hematopoietic cell–based gene therapy …